Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 4/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791455 | 1.00 | SLC10A1 (0.57) | SLC10A1CA9PTGESCA1CA2 | |
| SCHEMBL3797717 | 0.91 | NT5E (0.61) | SLC10A1CA9PTGESCA1CA2 | |
| SCHEMBL3797721 | 0.91 | NT5E (0.61) | SLC10A1CA9PTGESCA1CA2 | |
| SCHEMBL6119088 | 0.86 | RORC (0.50) | PTGESNT5EUSP2LMNAHIF1A | |
| SCHEMBL6119298 | 0.85 | SLC10A1 (0.65) | SLC10A1CA9PTGESCA1CA2 | |
| SCHEMBL6119253 | 0.83 | CA9 (0.67) | SLC10A1CA9PTGESCA1CA2 | |
| SCHEMBL3798874 | 0.83 | SLC10A1 (0.57) | SLC10A1CA9PTGESCA1CA2 | |
| SCHEMBL6112780 | 0.82 | PTPN1 (0.62) | SLC10A1CA9CA1CA2NT5E | |
| SCHEMBL3787385 | 0.81 | CA9 (0.62) | SLC10A1CA9PTGESCA1CA2 | |
| SCHEMBL3787381 | 0.81 | CA9 (0.62) | SLC10A1CA9PTGESCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969395-B2 | Triterpenoid derivatives useful as antiproliferative agents | UNIVERSIDADE DE COIMBRA (PT) | 2015-03-03 | — | — | US | disclosed |
| US-20120129901-A1 | TRITERPENOID DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | UNIVERSIDADE DE COIMBRA (PT) | 2012-05-24 | — | — | US | disclosed |
| WO-2010134830-A1 | TRITERPENOID DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | UNIVERSIDADE DE COIMBRA (PT) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129901-A1 | TRITERPENOID DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | ALPI, LSS, CYP46A1 | SLC10A1 43/4885CA9 362/4885PTGES 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.